Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues

British Journal of Pharmacology

Volumn 172, Issue 10, 2015, Pages 2433-2444

  Bonano, J S ^a,d   Banks, M L ^a   Kolanos, R ^a   Sakloth, F ^a   Barnier, M L ^a   Glennon, R A ^a   Cozzi, N V ^b   Partilla, J S ^c   Baumann, M H ^c   Negus, S S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; METHCATHINONE; SEROTONIN TRANSPORTER; BIOGENIC AMINE; MONOMETHYLPROPION; PROPIOPHENONE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN SYNAPTOSOME; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG ABUSE; FACILITATION; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MALE; MEDIAL FOREBRAIN BUNDLE; MONOAMINE RELEASE; NEUROCHEMISTRY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; SUBSTITUTION REACTION; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ELECTROSTIMULATION; METABOLISM; SELF STIMULATION; SYNAPTOSOME;

ANIMALS; BIOGENIC MONOAMINES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; MALE; PROPIOPHENONES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; SELF STIMULATION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTOSOMES;

EID: 84928331384     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13030     Document Type: Article

References (46)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
2. Archer RP, (2009). Fluoromethcathinone, a new substance of abuse. Forensic Sci Int 185: 10-20.
3. Bauer CT, Banks ML, Blough BE, Negus SS, (2013). Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br J Pharmacol 168: 850-862.
4. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB, (2011). In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337: 218-225.
5. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
6. Bonano JS, Glennon RA, Felice LJD, Banks ML, Negus SS, (2014). Abuse-related and abuse-limiting effects of methcathinone and the synthetic 'bath salts' cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology (Berl) 231: 199-207.
7. Cammarata A, Rogers KS, (1971). Electronic representation of the lipophilic parameter pi. J Med Chem 14: 269-274.
8. Cozzi NV, Sievert MK, Shulgin AT, Jacob P 3rd, Ruoho AE, (1999). Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381: 63-69.
9. Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, et al. (2013). Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur J Pharmacol 699: 180-187.
10. De Felice LJ, Glennon RA, Negus SS, (2014). Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology. Life Sci 97: 20-26.
11. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A, (2013). Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85: 1803-1815.
12. Findlay JW, Warren JT, Hill JA, Welch RM, (1981). Stereospecific radioimmunoassays for d-pseudoephedrine in human plasma and their application to bioequivalency studies. J Pharm Sci 70: 624-631.
13. Foley KF, Cozzi NV, (2003). Novel aminopropiophenones as potential antidepressants. Drug Dev Res 60: 252-260.
14. Gatch MB, Taylor CM, Forster MJ, (2013). Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav Pharmacol 24: 437-447.
15. Glennon RA, Young R, (2011) Drug discrimination and in vivo structure-activity relationships. In:, Glennon RA, Young R, (eds). Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies. Wiley: New York., pp. 163-165.
16. Glennon RA, Yousif M, Naiman N, Kalix P, (1987). Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 26: 547-551.
17. Hall C, Heyd C, Butler C, Yarema M, (2014). Bath salts' intoxication: a new recreational drug that presents with a familiar toxidrome. CJEM 16: 171-176.
18. Kaminski BJ, Griffiths RR, (1994). Intravenous self-injection of methcathinone in the baboon. Pharmacol Biochem Behav 47: 981-983.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Kohut SJ, Fivel PA, Blough BE, Rothman RB, Mello NK, (2013). Effects of methcathinone and 3-Cl-methcathinone (PAL-434) in cocaine discrimination or self-administration in rhesus monkeys. Int. J. Neuropsychopharmacol. 16: 1985-1998.
21. Kornetsky C, Esposito RU, (1979). Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38: 2473-2476.
22. Leffler AM, Smith PB, Armas A, de Dorman FL, (2014). The analytical investigation of synthetic street drugs containing cathinone analogs. Forensic Sci Int 234: 50-56.
23. Lespagnol A, Hallot J, (1954). Preparation of p-methoxyephedrone. Bulletin de la Societe de Pharmacie de Lille 45-46.
24. Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE, (1995). Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur J Pharmacol 287: 105-113.
25. Marusich JA, Grant KR, Blough BE, Wiley JL, (2012). Effects of synthetic cathinones contained in 'bath salts' on motor behavior and a functional observational battery in mice. Neurotoxicology 33: 1305-1313.
26. McDermott SD, Power JD, Kavanagh P, O'Brien J, (2011). The analysis of substituted cathinones. Part 2: an investigation into the phenylacetone based isomers of 4-methylmethcathinone and N-ethylcathinone. Forensic Sci Int 212: 13-21.
27. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
28. Negus SS, Miller LL, (2014). Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev 66: 869-917.
29. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-1106.
30. Prosser JM, Nelson LS, (2012). The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 8: 33-42.
31. Robinson JE, Agoglia AE, Fish EW, Krouse MC, Malanga CJ, (2012). Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine. Behav Brain Res 234: 76-81.
32. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
33. Rothman RB, Clark RD, Partilla JS, Baumann MH, (2003). (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. J Pharmacol Exp Ther 305: 1191-1199.
34. Sakloth F, Kolanos R, Mosier PD, Bonano JS, Banks ML, Partilla JS, et al. (2014). Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues. Br J Pharmacol doi: 10.1111/bph.13043.
35. Simmler LD, Rickli A, Hoener MC, Liechti ME, (2014). Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79: 152-160.
36. Spiller HA, Ryan ML, Weston RG, Jansen J, (2011). Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin. Toxicol. (Phila.) 49: 499-505.
37. Taft RW, (1952). Linear free energy relationships from rates of esterification and hydrolysis of aliphatic and ortho-substituted benzoate esters. J Am Chem Soc 74: 2729-2732.
38. Taft RW, (1953). Linear steric energy relationships. J Am Chem Soc 75: 4538-4539.
39. Trepanier DL, Sprancmanis V, (1964). 5,6-Dihydro-4H-1,3,4-oxadiazines. II. Structural requirements for effective hydrazido-hydroxyl interaction. J Org Chem 29: 673-677.
40. Vardakou I, Pistos C, Spiliopoulou C, (2011). Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 201: 191-195.
41. Vlachou S, Markou A, (2011) Intracranial self-stimulation. In:, Olmstead MC, (ed.). Animal Models of Drug Addiction. Humana Press: Totowa, NJ, pp. 3-56.
42. Wise RA, (1996). Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19: 319-340.
43. Wolff ME, (1980) The quantitative analysis of structure-activity relationships. In:, Wolff ME, (ed.). Burger's Medicinal Chemistry, 4th edn. Wiley: New York., pp. 393-418.
44. Yoshida T, Shimizu M, Harada M, Hitaoka S, Chuman H, (2012). Reassessment of Hammett σ as an effective parameter representing intermolecular interaction energy-links between traditional and modern QSAR approaches. Bioorg Med Chem Lett 22: 124-128.
45. Young R, Glennon RA, (1998). Discriminative stimulus effects of S(-)-methcathinone (CAT): a potent stimulant drug of abuse. Psychopharmacology (Berl) 140: 250-256.
46. Zuba D, Byrska B, (2013). Prevalence and co-existence of active components of 'legal highs'. Drug Test. Anal. 5: 420-429.